CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

被引：0
|
作者：
Venetsanakos, Eleni [1 ]
Stuart, Darrin [1 ]
Nguyen Tan [1 ]
Ye, Helen [1 ]
Salangsang, Fernando [1 ]
Aardalen, Kimberley [1 ]
Faure, Michel [1 ]
Heise, Carla [1 ]
Mendel, Dirk [1 ]
Jallal, Bahija [1 ]
机构：
[1] Chiron Corp, Emeryville, CA 94608 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4854
引用
收藏
页数：2
相关论文
共 18 条
  • [1] CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations
    Amiri, Payman
    Aikawa, Mina E.
    Dove, Jeff
    Stuart, Darrin D.
    Poon, Daniel
    Pick, Teresa
    Ramurthy, Savithri
    Subramanian, Sharadha
    Levine, Barry
    Costales, Abran
    Harris, Alex
    Paul, Renhow
    CANCER RESEARCH, 2006, 66 (08)
  • [2] Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 lInhibitor
    Tseng, Jeffrey R.
    Stuart, Darrin
    Aardalen, Kimberly
    Kaplan, Angelo
    Aziz, Natasha
    Hughes, Nicholas P.
    Gambhir, Sanjiv S.
    NEOPLASIA, 2011, 13 (03): : 266 - U108
  • [3] ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models
    Thompson, Scott K.
    Smith, Roger A.
    Rao, Niranjan
    Wick, Michael J.
    Reddy, Sanjeeva P.
    CANCER RESEARCH, 2017, 77
  • [4] Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines
    Teodorovic, Lenka S.
    Carrico, Jacqueline
    DeRyckere, Deborah
    Zhang, Weihe
    Wang, Xiaodong
    Frye, Stephen
    Eckhardt, S. Gail
    Earp, H. Shelton
    Graham, Douglas K.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models
    Gilmartin, A. G.
    Kusnierz, A. M.
    Sutton, D.
    Moss, K. G.
    Thompson, C. S.
    Weber, B. L.
    Copeland, R. A.
    Jackson, J. R.
    Laquerre, S. G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 178 - 178
  • [6] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Mesfer Al Shahrani
    Mohammad Abohassan
    Mohammad Y. Alshahrani
    Abdulrahim R. Hakami
    Prasanna Rajagopalan
    Journal of Computer-Aided Molecular Design, 2021, 35 : 1165 - 1176
  • [7] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Al Shahrani, Mesfer
    Abohassan, Mohammad
    Y. Alshahrani, Mohammad
    Hakami, Abdulrahim R.
    Rajagopalan, Prasanna
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2021, 35 (12) : 1165 - 1176
  • [8] A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
    Yin, Tinggui
    Lallena, Maria J.
    Kreklau, Emiko L.
    Fales, Kevin R.
    Carballares, Santiago
    Torrres, Raquel
    Wishart, Graham N.
    Ajamie, Rose T.
    Cronier, Damien M.
    Iversen, Phillip W.
    Meier, Timothy I.
    Foreman, Robert T.
    Zeckner, Douglas
    Sissons, Sean E.
    Halstead, Bart W.
    Lin, Aimee B.
    Donoho, Gregory P.
    Qian, Yuewei
    Li, Shuyu
    Wu, Song
    Aggarwal, Amit
    Ye, Xiang S.
    Starling, James J.
    Gaynor, Richard B.
    de Dios, Alfonso
    Du, Jian
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) : 1442 - 1456
  • [9] ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models
    Warren, W. G.
    Osborn, M.
    David-Pereira, A.
    Tsantoulas, C.
    Xue, Wenwen
    Yates, A.
    Osullivan, S. E.
    EUROPEAN JOURNAL OF PAIN, 2025, 29 (02)
  • [10] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Yong Xia
    Xuejiao Song
    Deliang Li
    Tinghong Ye
    Youzhi Xu
    Hongjun Lin
    Nana Meng
    Guobo Li
    Senyi Deng
    Shuang Zhang
    Li Liu
    Yongxia Zhu
    Jun Zeng
    Qian Lei
    Youli Pan
    Yuquan Wei
    Yinglan Zhao
    Luoting Yu
    Scientific Reports, 4
12